公开(公告)号：WO2010085780A1

公开(公告)日：2010-07-29

申请号：PCT/US2010/022045

申请日：2010-01-26

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICAL USA, INC. ,  SAMBURSKI, Guy ,  KURGAN, Ziv ,  MASARWA, Abed ,  SADYKHOV, Akper

Inventor： SAMBURSKI, Guy ,  KURGAN, Ziv ,  MASARWA, Abed ,  SADYKHOV, Akper

IPC: A61K9/16

CPC classification number: A61K9/5078 ,  A61K9/167 ,  A61K9/5089 ,  A61K31/41

Abstract: Processes for coating a carrier with microparticles of a drug are described. For example, a coated carrier can be obtained in a one-stage process that entails evaporating a solvent from microdroplets of a solution containing an API to obtain dry microparticles, which are then coated on the carrier.

Abstract translation: 描述了用药物微粒涂覆载体的方法。 例如，可以在一步法中获得涂覆的载体，其需要从含有API的溶液的微滴中蒸发溶剂以获得干燥的微粒，然后将其涂布在载体上。

公开(公告)号：WO2010039885A2

公开(公告)日：2010-04-08

申请号：PCT/US2009/059103

申请日：2009-09-30

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  RENDELL, Jacob ,  MITTELMAN, Ariel ,  MOSHKOVITS-KAPTSAN, Rinat ,  FINE, Sergei ,  KWOKAL, Ana ,  KOLTAI, Tamas

Inventor： RENDELL, Jacob ,  MITTELMAN, Ariel ,  MOSHKOVITS-KAPTSAN, Rinat ,  FINE, Sergei ,  KWOKAL, Ana ,  KOLTAI, Tamas

IPC: C07D401/12 ,  A61K31/44

CPC classification number: C07D401/12

Abstract: Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof.

Abstract translation: 提供了右兰索拉唑的结晶形式，以及其制备方法。

公开(公告)号：WO2010039798A2

公开(公告)日：2010-04-08

申请号：PCT/US2009/058975

申请日：2009-09-30

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  JEGOROV, Alexandr ,  GAVENDA, Ales ,  VRASPIR, Pavel ,  ARONHIME, Judith

Inventor： JEGOROV, Alexandr ,  GAVENDA, Ales ,  VRASPIR, Pavel ,  ARONHIME, Judith

IPC: A61K9/16 ,  A61K9/19 ,  A61K31/404 ,  A61P35/02

CPC classification number: A61K9/1635 ,  A61K9/1652 ,  A61K9/19 ,  A61K31/404 ,  C07D209/34

Abstract: Combinations of a pharmaceutically acceptable excipient selected from the group consisting of microcrystalline cellulose, polyvinylpyrrolidone, cyclodextrin, and disaccharide or derivatives thereof and acomposition of sunitinib base and L-malic acid were prepared.

Abstract translation: 制备选自微晶纤维素，聚乙烯吡咯烷酮，环糊精和二糖或其衍生物的药学上可接受的赋形剂和舒尼替尼碱和L-苹果酸的组合。

公开(公告)号：WO2010021745A2

公开(公告)日：2010-02-25

申请号：PCT/US2009/004783

申请日：2009-08-21

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  KANSAL, Vinod, Kumar ,  RANJAN, Harish ,  NAYAL, Sanjay ,  RAFILOVICH, Michal

Inventor： KANSAL, Vinod, Kumar ,  RANJAN, Harish ,  NAYAL, Sanjay ,  RAFILOVICH, Michal

IPC: C07D417/12

CPC classification number: C07D417/12

Abstract: The present invention provides crystalline forms of Rosiglitazone hydrobromide, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms.

Abstract translation: 本发明提供了罗格列酮氢溴酸盐的结晶形式，其制备方法，以及包含这些结晶形式的药物组合物。

公开(公告)号：WO2010008474A3

公开(公告)日：2010-01-21

申请号：PCT/US2009/003760

申请日：2009-06-23

Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD. ,  TEVA PHARMACEUTICALS USA, INC.

Inventor： KLINGER, Ety ,  TESSLER, Shoshi ,  HALLAK, Hussein ,  TACHAS, George ,  DIAMOND, Mark Paul

IPC: C07H21/00 ,  A61K31/7088

Abstract: A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby- treating the patient.

公开(公告)号：WO2009137098A1

公开(公告)日：2009-11-12

申请号：PCT/US2009/002877

申请日：2009-05-08

Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  FETELL, Michael, R.

Inventor： FETELL, Michael, R.

IPC: A01N43/62 ,  A61K31/55

CPC classification number: A61K31/55 ,  A61K31/4188 ,  A61K45/06 ,  A61K2300/00

Abstract: A method for treating a human subject afflicted with glioblastoma multiforme comprising periodically administering to the human subject an amount of (R) -7-Acetyl-5- (4- aminopheny 1 ) - 8, 9-dihydro-8-methyl-7H-l, 3-dioxolo [4, 5-H] [2, 3] benzodiazepine effective provide a benefit to the human subject, thereby treating the subject.

Abstract translation: 一种治疗患有多形性成胶质细胞瘤的人类受试者的方法，包括向所述受试者周期性施用一定量的（R）-7-乙酰基-5-（4-氨基苯基）-8,9-二氢-8-甲基-7H- 1,3-二氧杂环己烷[4,5-H] [2,3]苯并二氮杂有效地为人类受试者提供益处，从而治疗受试者。

公开(公告)号：WO2009120844A3

公开(公告)日：2009-10-01

申请号：PCT/US2009/038365

申请日：2009-03-26

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  KANARI, Itamar ,  LIEBOVICI, Minutza ,  FOX, Michael

Inventor： KANARI, Itamar ,  LIEBOVICI, Minutza ,  FOX, Michael

IPC: A61K9/20 ,  A61K9/50 ,  A61K31/00 ,  A61K31/4439 ,  A61K31/64

Abstract: Dosage forms containing an insulin sensitizer, such as pioglitazone, and an insulin secretogogue, such as glimepiride, are described. Including a cellulose derivative in the dosage form increased the dissolution rate of the insulin sensitizer and/or the insulin secretagogue.

公开(公告)号：WO2009120746A2

公开(公告)日：2009-10-01

申请号：PCT/US2009/038187

申请日：2009-03-25

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  PERLMAN, Nurit ,  RAMATY, Revital ,  ABRAMOV, Mili ,  FINKELSTEIN, Nina ,  LANCRY, Eli ,  ASIS, Shay ,  MITTELMAN, Ariel

Inventor： PERLMAN, Nurit ,  RAMATY, Revital ,  ABRAMOV, Mili ,  FINKELSTEIN, Nina ,  LANCRY, Eli ,  ASIS, Shay ,  MITTELMAN, Ariel

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7 ±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5 ±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7 ±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5 ±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7 ±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4 ±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66 ±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided.

Abstract translation: 磷酸西他列汀，其特征在于选自以下的数据：粉末XRD图谱，其峰为4.7,13.5,17.7,18.3和23.7±0.2度2θ; 在约4.7,13.5和15.5±0.2度2θ处具有峰的粉末XRD图案和至少另外两个选自以下列表的峰：14.0,14.4,18.3,19.2,19.5和23.7±0.2度2θ; 和具有在约13.5,19.2和19.5±0.2度2θ处以及从下列列表中选择的至少另外两个峰的峰的粉末XRD图：4.7,14.0,15.1,15.5,18.3和18.7±0.2度2θ; 在约13.5,15.5,19.2,23.7和24.4±0.2度2θ处具有峰的粉末XRD图案; 并且提供了在约4.65,13.46,17.63,18.30和23.66±0.10度2θ处具有峰的粉末XRD图案，制备所述西格列汀结晶形式的方法及其药物组合物。

公开(公告)号：WO2009089076A4

公开(公告)日：2009-07-16

申请号：PCT/US2009/000205

申请日：2009-01-12

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  INI, Santiago ,  SHMUELY, Yaron ,  PORTER-KLEKS, Osnat ,  CHEN, Kobi ,  LANCRY, Eli ,  SINGER, Claude

Inventor： INI, Santiago ,  SHMUELY, Yaron ,  PORTER-KLEKS, Osnat ,  CHEN, Kobi ,  LANCRY, Eli ,  SINGER, Claude

IPC: C07D471/04 ,  G01N30/86

Abstract: The present invention encompasses processes for the preparation and purification of paliperidone palmitate, for the purification of palmitic acid, for the preparation of paliperidone sodium salt and the preparation of paliperidone tetradecanoate or octadecanoate ester. The latter may further be used in a quantification method for determining the purity of paliperidone palmitate.

公开(公告)号：WO2009075776A1

公开(公告)日：2009-06-18

申请号：PCT/US2008/013394

申请日：2008-12-05

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  HEDVATI, Lilach ,  GILBOA, Eyal ,  AVHAR-MAYDAN, Sharon ,  SHACHAN-TOV, Sharona

Inventor： HEDVATI, Lilach ,  GILBOA, Eyal ,  AVHAR-MAYDAN, Sharon ,  SHACHAN-TOV, Sharona

IPC: C07D451/04 ,  A61K31/439 ,  A61P31/04

CPC classification number: C07D451/04

Abstract: Processes for preparing tropine derivatives of the following Formula B are provided where LG represents a leaving group. The tropine derivatives may be used to prepare Retapamulin, preferably in substantially pure form. Also provided are processes for preparing Retapamulin comprising combining a base, tropine thiol in a free base or salt form, an organic solvent, and a pleuromutilin derivative of Formula A.

Abstract translation: 提供制备下式B的托品衍生物的方法，其中LG代表离去基团。 托品衍生物可用于制备雷帕那普宁，优选以基本上纯的形式。 还提供了制备雷帕糊蛋白的方法，其包括将游离碱或盐形式的碱，托品硫硫醇，有机溶剂和式A的去甲孕素衍生物混合。